January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
August 2025 in “Indian Dermatology Online Journal” Both treatments work equally well for hair regrowth, but the lotion has fewer side effects.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
December 2025 in “Journal of health economics and outcomes research” Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
49 citations
,
October 2023 in “Journal of Dermatological Science”
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
14 citations
,
July 2021 in “Bioscience Reports” Activating Tgr5 may help treat hair loss and bone loss.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
September 2023 in “Journal of Cosmetic Dermatology” Lower vitamin D levels are linked to higher CRP levels in people with a type of hair loss called alopecia areata.
21 citations
,
April 2025 in “MedComm” Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
7 citations
,
February 2022 in “JAAD International” COVID-19 may be linked to hair loss or worsening of hair loss in some people.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
June 2023 in “Skin Research and Technology” High-resolution MRI can distinguish between tertiary androgenetic alopecia and severe alopecia areata by measuring scalp and tissue thickness and hair follicle depth.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
10 citations
,
January 2021 in “Annals of dermatology/Annals of Dermatology” Nivolumab can cause hair loss as a rare side effect.
5 citations
,
July 2024 in “Archives of Dermatological Research” 4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
2 citations
,
January 2020 in “Skin appendage disorders” Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
3 citations
,
July 2022 in “Indian journal of dermatology, venereology, and leprology” Patients with alopecia areata have higher oxidative stress and lower antioxidant levels.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.